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Whole-colon investigation vs. ﬂexible sigmoidoscopy for
suspected colorectal cancer based on presenting symptoms
and signs: a multicentre cohort study
Amanda J. Cross1, Kate Wooldrage1, Emma C. Robbins1, Kevin Pack1, Jeremy P. Brown1, William Hamilton2, Michael R. Thompson3,
Karen G. Flashman3, Steve Halligan4, Siwan Thomas-Gibson5, Margaret Vance5, Brian P. Saunders5 and Wendy Atkin1
BACKGROUND: Patients with suspected colorectal cancer (CRC) usually undergo colonoscopy. Flexible sigmoidoscopy (FS) may be
preferred if proximal cancer risk is low. We investigated which patients could undergo FS alone.
METHODS: Cohort study of 7375 patients (≥55 years) referred with suspected CRC to 21 English hospitals (2004–2007), followed
using hospital records and cancer registries. We calculated yields and number of needed whole-colon examinations (NNE) to
diagnose one cancer by symptoms/signs and subsite. We considered narrow (haemoglobin <11 g/dL men; <10 g/dL women) and
broad (<13 g/dL men; <12 g/dL women) anaemia deﬁnitions and iron-deﬁciency anaemia (IDA).
RESULTS: One hundred and twenty-seven proximal and 429 distal CRCs were diagnosed. A broad anaemia deﬁnition identiﬁed 80%
of proximal cancers; a narrow deﬁnition with IDA identiﬁed 39%. In patients with broad deﬁnition anaemia and/or abdominal mass,
proximal cancer yield and NNE were 4.8% (97/2022) and 21. In patients without broad deﬁnition anaemia and/or abdominal mass,
with rectal bleeding or increased stool frequency (41% of cohort), proximal cancer yield and NNE were 0.4% (13/3031) and 234.
CONCLUSION: Most proximal cancers are accompanied by broad deﬁnition anaemia. In patients without broad deﬁnition anaemia
and/or abdominal mass, with rectal bleeding or increased stool frequency, proximal cancer is rare and FS should sufﬁce.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0335-z
INTRODUCTION
Patients referred to hospital with suspected colorectal cancer
(CRC) typically undergo whole-colon investigation (WCI), predo-
minantly colonoscopy or computed tomography (CT) colonogra-
phy, in line with National Institute for Health and Care Excellence
(NICE) guidelines.1 In 2015, NICE issued a guideline on referral
criteria, including symptoms and signs conferring a positive
predictive value for cancer of 3%.2 Consequently, large numbers of
patients are undergoing WCI for suspected CRC, placing pressure
on endoscopy and radiology services and incurring substantial
costs to the National Health Service (NHS).3,4 Reducing the burden
of symptomatic referrals on diagnostic services is recognised as a
priority area for research.5
Flexible sigmoidoscopy is quicker, safer, less complicated, and
cheaper than colonoscopy. Intravenous sedation is usually not
needed and enemas used for preparation are associated with fewer
side effects and greater acceptability than oral preparations used for
WCI.6 Flexible sigmoidoscopy can be performed competently by
non-physician endoscopists7 and has high sensitivity for CRCs in the
distal colon and rectum8–10; however, it can only reach the splenic
ﬂexure at best and so abnormalities in the proximal colon are only
found if distal ﬁndings precipitate subsequent WCI.
Previous research has demonstrated that presenting symptoms/
signs are associated with CRC location.8–14 In the largest previous
study, Thompson et al. deﬁned a patient subgroup at low risk of
proximal cancer, for whom they deemed examination by ﬂexible
sigmoidoscopy alone appropriate.8 However, subsequent studies
reached variable conclusions regarding sole use of ﬂexible
sigmoidoscopy in any patient subgroup,9–14 and the current NICE
guidelines only recommend it for patients with major comorbidity,
in association with barium enema.1 The aim of the present
SOCCER (Symptoms of Colorectal Cancer Evaluation Research)
study15 was to further investigate whether presenting symptoms/
signs could be used to identify patients at low risk of proximal
cancer, for whom ﬂexible sigmoidoscopy would sufﬁce. This
would help alleviate the burden of WCI on patients and
endoscopy and radiology services.
METHODS
Study design and participants
We included patients who had been referred to 1 of the 21 English
NHS hospitals from 2004 to 2007 for investigation of symptoms/
signs suggestive of CRC. Of these hospitals, 8 were general and 13
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were teaching hospitals, and they varied from <40 to >1000 beds
in size.
We retrospectively identiﬁed patients from those who were
assessed for eligibility for the SIGGAR (Special Interest Group in
Gastrointestinal and Abdominal Radiology) trials. The SIGGAR trials
were two parallel randomised controlled trials assessing the
clinical and cost-effectiveness of CT colonography vs. barium
enema and colonoscopy for CRC diagnosis.16,17 To be eligible for
the SIGGAR trials, patients had to be ≥55 years and judged to be in
need of, and ﬁt enough for, a WCI with full bowel preparation.
Patients were ineligible if they were in follow-up for CRC, had
undergone WCI within the previous 6 months, had a known
diagnosis of familial adenomatous polyposis or Lynch syndrome,
or had previously been diagnosed with inﬂammatory bowel
disease (IBD).
Research nurses undertook the eligibility assessment, checking
endoscopy and radiology databases, and patient records and
notes. Only patients who were deemed eligible, gave informed
consent, and had a consultant consent to their participation were
randomised in the SIGGAR trials. Reasons for patient- and
consultant-declined consent included patients wanting to have
or avoid a speciﬁc type of WCI, consultants requesting a speciﬁc
procedure, and prior cancer diagnoses.
All patients who met the SIGGAR trial eligibility criteria
(regardless of whether they proceeded to randomisation) were
eligible for the SOCCER study, unless they were judged incapable
of giving informed consent, had dissented to use of their data for
research, had no symptoms/signs documented at presentation,
had duplicate study records, or were untraceable through NHS
Digital (Fig. 1).
Data collection and management
Research nurses or colorectal administrative assistants examined
patient records and notes, including referral letters, and recorded
demographic and clinical details on bespoke SIGGAR trial pro-
formas, including age, sex, general practitioner (GP)-reported
symptoms, route and urgency of referral, and planned diagnostic
investigations. There were tick boxes for ‘abdominal pain’,
‘anaemia’, ‘change in bowel habit (CIBH)’, ‘positive FOBT’ (faecal
occult blood test), ‘rectal bleeding’, and ‘weight loss’. Free text
ﬁelds were included to record additional symptoms/signs that
were coded and classiﬁed, and characteristics of reported CIBHs,
classiﬁed as ‘more frequent’, ‘less frequent’, ‘variable’, or ‘unspe-
ciﬁed’. Blood count data, additional clinical features, diagnostic
investigations performed, and diagnoses during the hospital
episode were ascertained through hospital record review.
For patients with blood count data, anaemia status was
determined according to the results of blood tests performed
within 6 months before and up to 3 months after referral. We
examined the prevalence of anaemia and iron-deﬁciency anaemia
(IDA) using two anaemia deﬁnitions: haemoglobin (Hb) <13 g/dL
in men and <12 g/dL in women (broad deﬁnition anaemia), used
by the World Health Organisation; and Hb < 11 g/dL in men and
<10 g/dL in women (narrow deﬁnition anaemia), as in the 2005
NICE referral guidelines.18,19 IDA was classiﬁed on the basis of
microcytosis (mean red cell corpuscular volume [MCV] <80 fL) or
serum ferritin <20 μg/L. For patients without blood count data, we
deﬁned anaemia based on whether the investigation of anaemia
was indicated as a reason for referral on the pro-forma.
CRC diagnoses occurring within 3 years of referral were
obtained from cancer registries, via NHS Digital, and hospital
records. CRC sites were deﬁned by International Classiﬁcation of
Diseases, tenth revision codes: proximal cancer included
C18.0–C18.5 (caecum to splenic ﬂexure) and distal cancer included
C18.6, C18.7, C19, C20, and C21 (descending colon to anus). CRC
morphologies were deﬁned by International Classiﬁcation of
Diseases for Oncology, second edition codes; we included codes
related to invasive and in situ carcinomas (8000/3, 8010/3, 8070/3,
8123/3, 8140/2, 8140/3, 8144/3, 8210/3, 8261/2, 8261/3, 8263/2,
8263/3, 8480/3, 8481/3, 8490/3, 8510/3, and 8560/3).
Statistical analysis
The primary outcome was the yield of proximal vs. distal cancer
within 3 years of referral by presenting symptom/sign. Yields were
calculated as the number of patients with proximal or distal cancer
divided by the number of patients with a particular symptom/sign,
presented as percentages. Secondary outcomes included the
number of needed whole-colon examinations (NNE) to detect one
proximal vs. distal cancer by presenting symptom/sign, calculated
by inverting the yield and presented with binomial exact 95%
conﬁdence intervals (CIs). For this calculation, we made the
assumption that WCI has perfect sensitivity for detecting proximal
and distal cancers.
We calculated the sensitivity of symptoms/signs for proximal
and distal cancer and the proportion of patients with CRC who
had proximal vs. distal cancer by presenting symptom/sign. We
also calculated the proportion of CRCs that would have been
missed if certain symptoms/signs were investigated by ﬂexible
sigmoidoscopy alone, with binomial exact 95% CIs, assuming that
ﬂexible sigmoidoscopy would have detected all distal cancers but
not proximal cancers.
We estimated that, with a sample size of 8,484 patients, giving
rise to an estimated 68 proximal and 421 distal cancers, we could
estimate with sufﬁcient precision the proportion of CRCs that
would have been missed if certain symptoms/signs were
investigated by ﬂexible sigmoidoscopy alone. Data analyses were
conducted using Stata/IC 13.1 (StataCorp. 2013. Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP).
RESULTS
A total of 8484 patients referred to hospital with suspected CRC
were assessed for eligibility for the SIGGAR trials. Of these, 5448
were randomised to the SIGGAR trials and 3036 were not (Fig. 1).
Comparing randomised and non-randomised patients, the former
were younger and less likely to have been referred from a
colorectal surgical outpatient clinic and via the urgent pathway
(data not shown).
Of the total 8484 patients, all of whom were deemed eligible for
the SOCCER study, 1109 were subsequently excluded, primarily
due to patient dissent to use of their data for research. This left
7375 patients for our cohort analysis (Fig. 1). The median age of
included patients was 69 years (interquartile range: 62–76) and
59.0% were women. The majority of patients were referred from a
colorectal surgical outpatient clinic (84.5%) and via the urgent
pathway (71.7%) (Table 1), and 1483 (20.1%) had undergone
ﬂexible sigmoidoscopy at the time of referral (data not shown).
In total, 556 CRCs were diagnosed in 551 of the 7375 patients
(7.5%) within 3 years following referral (Table 2). Of the 551
patients with CRC, 522 (94.7%) were diagnosed within 6 months
post-referral (data not shown). There were 127 proximal and 429
distal cancers (5 patients had synchronous proximal and distal
cancer), giving diagnostic yields of 1.7% for proximal cancer and
5.8% for distal cancer (Table 2). Detailed subsite information is
presented in Supplementary Table 1.
Blood count data were not available for all patients. Data on Hb
and MCV were available for 4742 of 7375 patients (64.3%). There
were 1157 patients (15.7%) with serum ferritin in addition to Hb
and MCV counts (Table 1). Comparing the 4742 patients with Hb
and MCV data to the 2633 patients without, those with data
available were older and less likely to have been referred from a
colorectal outpatient clinic (Supplementary Table 2).
Among the 4742 patients with blood count data, narrow
deﬁnition anaemia was present in 672 (14.2%) and narrow
deﬁnition anaemia with IDA was present in 363 (7.7%). Broad
deﬁnition anaemia was present in 1660 (35.0%) and broad
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deﬁnition anaemia with IDA in 567 (12.0%) (Table 2). The
prevalence of anaemia increased with age among men and
women. Broad deﬁnition anaemia was present in 23.8% (131/551)
of men and in 18.6% (161/867) of women aged 55–64 years and in
73.3% (66/90) of men and 57.2% (83/145) of women aged ≥85
years. This pattern of anaemia increasing with age was also
observed when considering the other anaemia deﬁnitions and IDA
(data not shown). Among the 2633 patients without blood count
data, investigation of anaemia was a reason for referral in 229
(8.7%) (Table 2).
Anaemia and cancer site
Among the 4742 patients with blood count data, there were 97
proximal and 240 distal cancers. While yields of distal cancer did
not vary by anaemia status, anaemia was strongly associated with
proximal cancer (Table 2). Proximal cancer yield was 0.6% (19/
3082) in patients without anaemia, increasing to 10.5% (38/363) in
patients with narrow deﬁnition anaemia and IDA. Broadening the
deﬁnition of anaemia and removing the requirement for IDA
reduced the yield to 4.7% (78/1660). Among the 2633 patients
without blood count data, yield of proximal cancer was 3.9% (9/
229) in patients referred for investigation of anaemia vs. 0.9% (21/
2404) in those who were not (Table 2).
Although the yield of proximal cancer was highest in patients
with narrow deﬁnition anaemia and IDA, this criterion identiﬁed
39.2% (38/97) of patients with proximal cancer, while the broad
deﬁnition of anaemia (with or without IDA) identiﬁed 80.4% (78/
97) (Table 2). We therefore used the broad deﬁnition in all
subsequent analyses of patients with blood count data (n= 4742)
to ensure high sensitivity of anaemia for proximal cancer. For
patients without blood count data (n= 2633), we deﬁned anaemia
based on whether the investigation of anaemia was indicated as a
reason for referral. Among all 7375 patients, 1889 (25.6%) had
either broad deﬁnition anaemia (n= 1660) or were referred for
investigation of anaemia (n= 229) (Table 2).
8484 referred with suspected CRC
5448 randomised in SIGGAR
3036 not randomised in SIGGAR
7375 in SOCCER cohort
4742 with blood count data
2633 without blood count data
1109 excluded from SOCCER
936 dissented to use of data in
future research
75 judged unable to provide
informed consent
32 had no symptoms/signs recorded
at presentation
10 had duplicate study records
56 not traceable with NHS Digital 
Fig. 1 Flow chart of study participants CRC colorectal cancer, SIGGAR Special Interest Group in Gastrointestinal and Abdominal Radiology,
SOCCER Symptoms of Colorectal Cancer Evaluation Research. The SOCCER study included patients who had been referred to hospital with
suspected CRC and assessed for eligibility for the SIGGAR trials. All patients who met the SIGGAR trials eligibility criteria (regardless of whether
they proceeded to randomisation) were eligible for the SOCCER study, unless they had dissented to use of their data in future research, were
judged unable by a clinician to provide informed consent for the use of their data in future research, had no symptoms/signs recorded at
presentation, had duplicate study records, or were not traceable with NHS Digital. Among those included in the SOCCER study, data on
haemoglobin and mean red cell corpuscular volume were available for 4742 of the 7375 patients
Table 1. Patient characteristics (N= 7375)
Characteristic N %
Sex
Men 3023 41.0
Women 4352 59.0
Age (years)
55–64 2407 32.6
65–74 2739 37.1
75–84 1896 25.7
≥85 333 4.5
Route of referral
Colorectal surgical outpatient clinic 6231 84.5
Other outpatient clinic 688 9.3
Straight to test 396 5.4
Hospital admission 33 0.4
Not recorded 27 0.4
Urgency of referral
Urgent 5290 71.7
Soon 660 9.0
Routine 914 12.4
Not recorded 511 6.9
Availability of blood count dataa
Hb and MCV 4742 64.3
Serum ferritin 1157 15.7
None available 2633 35.7
aAll patients with serum ferritin had a haemoglobin (Hb) and mean red cell
corpuscular volume (MCV) count
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Symptoms and signs related to cancer site
Among all patients, the most common symptoms/signs were a
CIBH (73.0%, n= 5382), rectal bleeding (37.6%, n= 2773),
abdominal pain (28.8%, n= 2126), weight loss (15.6%, n= 1148),
and anaemia (25.6%, n= 1889) (Table 3). Most patients presented
with more than one symptom/sign (Supplementary Table 3).
Yields of proximal and distal cancer varied considerably by
symptom/sign (Table 3). The highest yields of distal cancer were
among patients with rectal mass (28.5%, 47/165) and rectal
bleeding (10.5%, 291/2773). Yields of proximal cancer were
generally lower than for distal cancer, with the highest yields
among patients with abdominal mass (9.3%, 20/216) and anaemia
(4.6%, 87/1889). Yields of proximal and distal cancer were
generally higher when patients presented with a combination of
symptoms/signs (Table 3).
The location of diagnosed cancers was also inﬂuenced by
symptom/sign (Table 4). Rectal bleeding was associated with an
approximate 90% chance that cancer was distal, irrespective of
additional symptoms. Anaemia and abdominal mass were
associated with a high probability that cancer was proximal
(41.4% and 51.3%, respectively), irrespective of additional
symptoms.
We evaluated the combination of anaemia and/or abdominal
mass in further detail, given the strong association with proximal
cancer. Among the 2022 patients with anaemia and/or abdominal
mass, proximal cancer yield was 4.8%, the NNE was 21 (95% CI
18–26), and 42.0% of the patients with cancer had proximal
cancer. The sensitivity of anaemia and/or abdominal mass for
proximal cancer was 76.4% (97/127) (Table 5).
Among the 5353 patients without anaemia and/or abdominal
mass, the yield of proximal cancer was 0.6% (NNE 179, 95% CI
126–265). Proximal cancer yield was also 0.6% (NNE 169, 95% CI
99–317) among the 2195 patients without anaemia and/or
abdominal mass who had rectal bleeding. No proximal cancers
were found in 836 patients without anaemia and/or abdominal
mass who presented with a CIBH to increased frequency alone
(Table 5).
There were 3031 patients without anaemia and/or abdominal
mass who had rectal bleeding or solely a CIBH to increased
frequency, accounting for 41.1% of the cohort. Among these
patients, 236 distal cancers were diagnosed (yield of 7.8%; NNE 13,
95% CI 12–15) while only 13 proximal cancers were diagnosed
(yield of 0.4%; NNE 234, 95% CI 137–438) (Table 5). Yields of
proximal cancer were <1% for all age ranges in this patient
subgroup (data not shown). Of the 13 proximal cancer patients, 6
had distal ﬁndings that would warrant WCI (Supplementary
Table 4). Therefore, if this patient subgroup were investigated
by ﬂexible sigmoidoscopy alone, 7 of the total 556 cancers (1.3%,
95% CI 0.5–2.6%) would have been missed. For ﬁve of these seven
cases, blood count data were not available and so anaemia at
presentation cannot be ruled out.
Flexible sigmoidoscopy is considered complete if the
sigmoid–descending colon junction is reached20; therefore,
cancers in the descending colon may be missed. Descending
colon cancers were rare in our study (1.4%, 8/556). Of the eight
patients with descending colon cancers, two had the symptom
proﬁle of rectal bleeding or solely a CIBH to increased frequency
without anaemia and/or abdominal mass; one of these had a
synchronous cancer in the sigmoid colon while the other had no
important distal ﬁndings (Supplementary Table 5).
DISCUSSION
For patients referred to hospital with suspected CRC, an important
decision is whether to offer WCI or ﬂexible sigmoidoscopy. NHS
clinics offering rapid access ﬂexible sigmoidoscopy have been
shown to be suitable for evaluation of urgently referred patients,
with a low miss rate of proximal cancer.9,11 However, fear of
missing proximal cancers remains, with 20–70% of patients
proceeding to WCI following ﬂexible sigmoidoscopy.8,9,11,21 This
negates the convenience and cost-effectiveness of ﬂexible
sigmoidoscopy, particularly as subsequent WCI has a very low
cancer yield.8,9 To address the fear of missing cancers in patients
examined solely by ﬂexible sigmoidoscopy, we sought to
determine in which patients the yield of proximal cancer and
the probability of missing proximal cancer is low.
This multicentre cohort study of 7375 patients referred with
suspected CRC to 21 hospitals throughout England validates
previous studies that showed how yields of proximal and distal
cancer vary by presenting symptom/sign.8–14 The largest previous
study of 16,433 patients referred to hospital from 1986 to 2001
concluded that ﬂexible sigmoidoscopy alone was sufﬁcient for
patients with a CIBH, rectal bleeding, and/or abdominal pain but
without IDA, abdominal mass, severe symptoms, or signiﬁcant
ﬂexible sigmoidoscopy ﬁndings. This was based on the ﬁnding
that proximal cancer was very rare (<1%) in such patients.8 In an
extension of this study, including data collected from 1986 to
2007, proximal cancer was again associated with IDA and
abdominal mass but not with a CIBH or rectal bleeding.22
Our study conﬁrms the strong association between anaemia
and abdominal mass with proximal cancer and newly demon-
strates the importance of adopting a broad deﬁnition of anaemia.
We found that 80% of proximal cancer cases could be identiﬁed
using the broad deﬁnition (with or without IDA), compared to 39%
using the narrow deﬁnition with requirement for IDA. The broad
deﬁnition should therefore be adopted when selecting patients
for ﬂexible sigmoidoscopy since there is a greater likelihood
of missing proximal cancers with the narrower deﬁnition. Given
the importance of anaemia as a marker for proximal cancer, we
also recommend that all patients referred with suspected CRC
have a full blood count, unless an emergency investigation is
required.
Through closer examination of cancer yield by combinations
of symptoms and signs, we were able to deﬁne the criteria for
ﬂexible sigmoidoscopy more speciﬁcally. Proximal cancer risk
was particularly low in patients without anaemia and/or
abdominal mass who presented with a CIBH to increased
frequency alone. Similarly, very few proximal cancers were
detected in patients without anaemia and/or abdominal mass
who presented with rectal bleeding, alone or with other
symptoms/signs. These novel ﬁndings led us to conclude that
ﬂexible sigmoidoscopy alone is sufﬁcient for patients without .
anaemia and/or abdominal mass who present with any rectal
bleeding or solely a CIBH to increased frequency, unless there
are signiﬁcant distal ﬁndings that warrant WCI (i.e. large or
multiple adenomas, IBD) or the examination is incomplete.
Patients ﬁtting these criteria could be reassured that their risk of
proximal cancer is very low but that they should return to their
GP if symptoms continue. In our study, 41% of patients fulﬁlled
these criteria for ﬂexible sigmoidoscopy alone.
The probability of missing a proximal cancer is an important
consideration. In the study by Thompson et al., 131 proximal
cancers were diagnosed.8 Of the 37 cases without anaemia and/or
abdominal mass, 20 would have undergone subsequent WCI
because of severe symptoms or signiﬁcant ﬂexible sigmoidoscopy
ﬁndings. Thus 17 proximal cancers (13%) would have been missed
if only ﬂexible sigmoidoscopy was undertaken. With our criteria
for ﬂexible sigmoidoscopy, 10 proximal cancers (8%) would have
been missed in the Thompson data, and probably fewer if our
broad anaemia deﬁnition had been considered. Adoption of our
ﬂexible sigmoidoscopy criteria would therefore minimise the
probability of missing proximal cancers.
There is a small risk that distal cancers could go undetected if
ﬂexible sigmoidoscopy is undertaken alone. While ﬂexible
sigmoidoscopy, in theory, can reach the splenic ﬂexure, the
descending colon sometimes goes unexamined as there are no
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anatomical markers that the splenic ﬂexure has been reached.20,23
Few cancers are, however, located in the descending colon.24 In
our study, 8 of the 429 distal cancers were in the descending
colon and only 1 of the 8 patients would have undergone ﬂexible
sigmoidoscopy alone with our criteria.
There is also a small risk of missing cancers in the sigmoid colon
with ﬂexible sigmoidoscopy. Examinations failing to reach the
sigmoid–descending colon junction are, however, typically
deemed incomplete,20,23,25 prompting subsequent whole-colon
completion examination.8,9,21 It is worth noting that, although
studies have reported high rates of incomplete examinations due
to pain, faeces, or scope looping, these were based on ﬂexible
sigmoidoscopy performed over 10 years ago.23,25 There are now
remedies to avoid these scenarios. Premixed 50% nitrous oxide
and oxygen (Entonox, BOC Healthcare, Guildford, Surrey, UK) has
been shown to be as effective as conventional sedation for
colonoscopy and is used frequently for ﬂexible sigmoidoscopy
screening in the English Bowel Cancer Screening programme.26
Preparation for ﬂexible sigmoidoscopy usually involves a single
phosphate enema,6 although oral preparations are occasionally
used. If the distal bowel is not adequately cleared by an initial
enema, a second can be administered via the endoscope. This has
proved highly effective in patients having inadequate bowel
preparation at colonoscopy.27
Isolated proximal non-cancerous abnormalities could also be
missed by undertaking ﬂexible sigmoidoscopy alone. Few studies,
however, have addressed this.28,29 One retrospective study of
1766 patients who had undergone colonoscopy for rectal
bleeding found isolated proximal colitis in 26 (1.5%) patients.28
Similarly, in a study of 625 patients aged <50 years with diarrhoea,
10 (1.6%) had isolated proximal IBD or colitis.29 Microscopic colitis,
a common cause of unexplained chronic diarrhoea, presents a
particular challenge as it can only be diagnosed on colonic biopsy
and the vast majority of patients who receive a diagnosis have
macroscopically normal colons.30 Although limited, the current
evidence indicates that, when microscopic colitis is present, it is
present throughout the colon.31,32 It is therefore likely that distal
biopsies taken during ﬂexible sigmoidoscopy would be sufﬁcient
for diagnosis.
Our study has several strengths, including recruitment from
multiple hospitals, detailed baseline patient information, and
follow-up using cancer registries for 3 years post-referral. We are
conﬁdent that the follow-up period was sufﬁciently long to
capture all incident CRC cases as the vast majority of CRCs were
diagnosed within 6 months, with very few diagnosed in the
ensuing 3 years.
Limitations include a possible selection bias since all patients
were aged ≥55 years, considered ﬁt for WCI, and 72% were
urgently referred. Some patients did not proceed to undergo WCI
but we were unable to accurately identify these patients from
hospital records; nevertheless, we are conﬁdent that we did
not miss cancers because we had cancer registry data for 3 years
post-referral. Reporting bias is possible as the recording of
symptoms by medical staff may have been inﬂuenced by what
investigations were planned or by the presumed signiﬁcance of
the symptoms.33
A further limitation is that we did not have blood count data on
all patients; for those patients without this data, anaemia was
deﬁned by whether it was indicated as a reason for referral. With
full blood count data, it is possible that even fewer proximal
cancer cases would have been missed by our ﬂexible sigmoido-
scopy criteria, as a greater proportion may have had anaemia.
Finally, it is important to note that the cohort was gathered before
the Bowel Cancer Screening Programme was fully rolled out in
England. It is now common in clinical practice to consider the
screening history of patients along with how recently any colonic
examinations have taken place when selecting the most appro-
priate diagnostic investigation.
CONCLUSION
Our ﬁndings conﬁrm the strong association between anaemia and
proximal cancer, with 80% of proximal cancer patients in our
cohort meeting the criteria for broad deﬁnition anaemia. All
patients with suspected CRC should therefore have a full blood
count, unless an emergency investigation is needed, and patients
identiﬁed as anaemic according to the broad deﬁnition of
anaemia should be referred for WCI. Conversely, the risk of
proximal cancer is very low in patients without broad deﬁnition
anaemia and/or abdominal mass but who present with any rectal
bleeding or solely a CIBH to increased frequency. Patients with this
symptom proﬁle can be examined safely by ﬂexible sigmoido-
scopy alone. If incorporated into guidelines, this strategy would
greatly reduce the number of WCIs performed in patients at low
risk of proximal cancer; this would alleviate the burden of WCI on
patients and endoscopy and radiology services.
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